

Rebyota® (fecal microbiota, live-jslm)
Effective 06/30/2023

Plan	<input checked="" type="checkbox"/> MassHealth UPPL <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit		
Specialty Limitations	N/A		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
Exceptions	N/A		

Overview

Rebyota® (fecal microbiota, live-jslm) is a rectally administered fecal microbiota transplantation (FMT) for the prevention of recurrence of Clostridioides difficile infection (CDI) in patients 18 years of age or older following antibiotic treatment for recurrent CDI.

Coverage Guidelines

Authorization may be granted for members when all the following criteria are met, and documentation is provided:

1. Diagnosis for prevention of recurrent CDI with \geq two episodes of CDI following initial infection (\geq three total episodes of CD including initial infection)
2. Prescriber is an infectious disease specialist or gastroenterologist or consult notes from a specialist are provided
3. Member is \geq 18 years of age
4. **If reviewing under Pharmacy Benefit:** Physician attestation of inadequate response, adverse reaction, or contraindication to Zinplava® (bezlotoxumab)
5. Medical necessity for requested agent instead of fecal microbiota transplant via other methods (e.g., IND protocol, stool banks)‡
6. Requested quantity is \leq single dose

‡ Contraindication to or patient unwillingness to undergo colonoscopy are acceptable medical necessities to bypass FMT via other methods

Limitations

1. Initial approvals will be granted for 1 month.
2. Reauthorizations of Rebyota® (fecal microbiota, live-jslm) will not be granted as it has not been studied for greater than a one-time administration.

References

1. Rebyota® (fecal microbiota, live -jslm) [package insert]. Roseville, MN: Ferring Pharmaceuticals Inc.; January 2023.

Review History

05/10/2023 - Created for P&T. New drug, Rebyota (fecal microbiota, live-jslm), will now have a prior authorization. Effective 6/5/23.

06/14/23 – Reviewed and updated for P&T. Removed preferred product requirement for requests through MB. Effective 6/30/23.

